VIDEO: Tinengotinib shows promise for previously untreated cholangiocarcinoma
In this video, Rachna T. Shroff, MD, MS, discusses updated data on tinengotinib, presented at ASCO Gastrointestinal Cancers Symposium.
Tinengotinib (TransThera Biosciences), a new generation FGFR inhibitor, has demonstrated notable responses in patients with FGFR-altered cholangiocarcinoma.“In this novel generation of drugs, we’re also seeing that some of these drugs can overcome some of the known resistance mechanisms from the first cadre of drugs that we have available to us through the FDA approvals," Shroff, of University of Arizona Cancer Center, said. “That data is really exciting because it demonstrates what we know is an on-target proof of principle that we can use FGFR inhibitors in FGFR fusion and gene rearrangements.”
Reference:
- Javle M, et al. Abstract 434. Presented at: ASCO Gastrointestinal Cancers Symposium; Jan. 18-20, 2024; San Francisco.
Collapse
Healio Interviews